Christopher R Gibson

List of Publications by Year
in descending order

33	1,138	471509 17	395702 33
papers	citations	h-index	g-index

35	35	35	1383
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Drugâ€“Drug Interaction Studies: Regulatory Guidance and An Industry Perspective. AAPS Journal, 2013, 15, 629-645.	4.4	193
2	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. Journal of Pharmaceutical Sciences, 2011, 100, 4090-4110.	3.3	165
3	PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentrationâ€“time profiles in human by using the physiologicallyâ€based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences, 2011, 100, 4127-4157.	3.3	152
4	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. Journal of Pharmaceutical Sciences, 2011, 100, 4074-4089.	3.3	105
5	PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets. Journal of Pharmaceutical Sciences, 2011, 100, 4050-4073.	3.3	55
6	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentrationâ€“time profiles in human from in vivo preclinical data by using the Wajima approach. Journal of Pharmaceutical Sciences, 2011, 100, 4111-4126.	3.3	51
7	Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas. Neurosurgery, 2000, 47, 608-622.	1.1	49
8	Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. AAPS Journal, 2015, 17, 462-473.	4.4	43
9	Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas. Neurosurgery, 2000, 47, 608-622.	1.1	39
10	Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-methyltransferase Inhibitors and Substrates. ACS Chemical Neuroscience, 2012, 3, 129-140.	3.5	35
11	Discovery of GlyT1 inhibitors with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1492-1495.	2.2	23
12	Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Medicinal Chemistry, 2015, 7, 2351-2369.	2.3	22
13	EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY. Drug Metabolism and Disposition, 2006, 34, 1361-1366.	3.3	21
14	Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica, 2009, 39, 637-648.	1.1	21
15	Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica, 2013, 43, 1027-1036.	1.1	19
16	Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Drug Discovery Today, 2017, 22, 1447-1459.	6.4	18
17	Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs â€“ midazolam and odanacatib. Journal of Clinical Pharmacology, 2014, 54, 1280-1289.	2.0	17
18	Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. Clinical Pharmacology and Therapeutics, 2019, 105, 1018-1030.	4.7	16

#	Article	IF	Citations
19	Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy. Journal of Neuro-Oncology, 2003, 62, 157-169.	2.9	13
20	BIOACTIVATION OF THE 3-AMINO-6-CHLOROPYRAZINONE RING IN A THROMBIN INHIBITOR LEADS TO NOVEL DIHYDRO-IMIDAZOLE AND IMIDAZOLIDINE DERIVATIVES: STRUCTURES AND MECHANISM USING 13C-LABELS, MASS SPECTROMETRY, AND NMR. Drug Metabolism and Disposition, 2003, 31, 1437-1447.	3.3	12
21	Electrospray Ionization Mass Spectrometry Coupled To Reversed-Phase Ion-Pair High-Performance Liquid Chromatography for Quantitation of Sodium Borocaptate and Application To Pharmacokinetic Analysis. Analytical Chemistry, 2002, 74, 2394-2399.	6.5	11
22	In vitro metabolism of a thrombin inhibitor and quantitation of metabolically generated cyanide. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 1014-1020.	2.8	10
23	Synthesis and optimization of N -heterocyclic pyridinones as catechol- O -methyltransferase (COMT) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2952-2956.	2.2	8
24	Measurement of total liver blood flow in intact anesthetized rats using ultrasound imaging. Pharmacology Research and Perspectives, 2021, 9, e00731.	2.4	7
25	Identification of diethylene glycol monobutyl ether as a source of contamination in an ion trap mass spectrometer. Journal of the American Society for Mass Spectrometry, 2003, 14, 1247-1249.	2.8	5
26	INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY. Drug Metabolism and Disposition, 2005, 33, 1044-1051.	3.3	5
27	Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. Pharmaceutical Research, 2020, 37, 181.	3.5	4
28	siRNA-Mediated Knockdown of P450 Oxidoreductase in Rats: A Tool to Reduce Metabolism by CYPs and Increase Exposure of High Clearance Compounds. Pharmaceutical Research, 2014, 31, 3445-3460.	3.5	3
29	Title is missing!. Journal of Neuro-Oncology, 2003, 62, 157-169.	2.9	2
30	Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects. Journal of Clinical Pharmacology, 2017, 57, 110-117.	2.0	2
31	Variability in Human In Vitro Enzyme Kinetics. Methods in Molecular Biology, 2021, 2342, 443-479.	0.9	2
32	Translational Pharmacokineticâ€“Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in Pharmacology, 2021, 12, 786078.	3.5	2
33	Variability in Human In Vitro Enzyme Kinetics. Methods in Molecular Biology, 2014, 1113, 337-362.	0.9	1